Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven®) after allogenic bone marrow transplantation [2]

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 10, 2004, Pages 1853-1855

  Karimi, Mehran ^a   Zakerinia, M ^b   Khojasteh, H N ^b   Ramzi, M ^b   Ahmad, E ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; LYMPHOCYTE ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTERY LIGATION; BLADDER IRRIGATION; BLOOD TRANSFUSION; CASE REPORT; CHILD; CYSTECTOMY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATALITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HEMOPHILIA; HEMORRHAGIC CYSTITIS; HUMAN; ILEAL CONDUIT; INFECTION; IRAN; LETTER; LEUKEMIA; LYMPHOMA; MALE; PATIENT CARE; PRIORITY JOURNAL; SURGICAL RISK; THALASSEMIA MAJOR;

ADULT; BONE MARROW TRANSPLANTATION; CHILD; CYCLOPHOSPHAMIDE; CYSTITIS; DRUG EVALUATION; FACTOR VII; FEMALE; HEMATOLOGIC DISEASES; HEMORRHAGE; HUMANS; MALE; RECOMBINANT PROTEINS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 13244255246     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00917.x     Document Type: Letter

References (14)

1. Firlit CF. Intractable hemorrhagic cystitis secondary to extensive carcinomatosis: management with formalin solution. J Urol 1973; 110: 57-9.
2. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3953.
3. Martionwitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-9.
4. Kamphuisen PW, van den Akker JM, Kaasjager KA, Bloemen TI. Control of life-threatening pulmonary bleeding with activated recombinant factor VII. Am J Med 2002; 112: 332-3.
5. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
6. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-bind placebo-controlled randomized trial. Lancet 2003; 18: 361: 201-5.
7. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®). J Thromb Haemost 2003; 1: 450-5.
8. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163-76.
9. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomized trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
10. Hattori K, Yabe M, Matsumoto M, Kudo Y, Yasuda Y, Inoue H, Minami S, Miyakita H, Kawamura N, Komori K, Yamamoto I, Yabe H. Successful hyperbaric oxygen treatment of life-threatening hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 27: 1315-7.
11. Shah BC, Albert DJ. Intravesical instillation of formalin for the management of intractable hematuria. J Urol 1973; 110: 519-20.
12. Gallistl S, Cvirn G, Muntean W. Recombinant factor VIIa doesn't induce hypercoagulability in vitro. Thromb Haemost 1999; 81: 245-9.
13. Baudo F, Redaelli R, Caimi TM, Mostarda, G, Somaini G, de Cataldo F. The continuse infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000; 99: 21-4.
14. Peerlink Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven®) in a patient with hemophilia A and inhibitor. Thromb Haemost 1999; 82 1775-6.